Sanuwave Health (NASDAQ:SNWV) Trading Down 11% – What’s Next?

Sanuwave Health Inc. (NASDAQ:SNWV) shares traded down 11% during mid-day trading on Thursday . The stock traded as low as $7.53 and last traded at $7.63. Approximately 201,905 shares changed hands during mid-day trading, an increase of 20% from the average daily volume of 168,855 shares. The stock had previously closed at $8.57.

Wall Street Analysts Forecast Growth

SNWV has been the topic of several recent research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Sanuwave Health in a research report on Wednesday. Roth Mkm reissued a “buy” rating and issued a $47.00 target price (down from $53.00) on shares of Sanuwave Health in a research report on Monday, March 30th. Zacks Research downgraded shares of Sanuwave Health from a “hold” rating to a “strong sell” rating in a research note on Monday, March 30th. Finally, Wall Street Zen lowered shares of Sanuwave Health from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.00.

Sanuwave Health Trading Up 12.8%

The stock has a market capitalization of $74.04 million, a P/E ratio of 26.09 and a beta of 1.34. The company has a current ratio of 1.31, a quick ratio of 0.99 and a debt-to-equity ratio of 8.15. The business has a 50-day moving average price of $15.25 and a two-hundred day moving average price of $21.64.

Sanuwave Health (NASDAQ:SNWV) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). Sanuwave Health had a negative return on equity of 450.56% and a net margin of 35.96%.The company had revenue of $9.62 million during the quarter, compared to the consensus estimate of $9.60 million.

Institutional Trading of Sanuwave Health

Several large investors have recently made changes to their positions in SNWV. Legal & General Group Plc acquired a new position in Sanuwave Health during the second quarter valued at approximately $26,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Sanuwave Health by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,398 shares of the company’s stock valued at $728,000 after purchasing an additional 1,135 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Sanuwave Health by 4.9% in the 1st quarter. Bank of America Corp DE now owns 25,503 shares of the company’s stock valued at $441,000 after purchasing an additional 1,182 shares in the last quarter. Barclays PLC increased its stake in shares of Sanuwave Health by 12.7% in the 4th quarter. Barclays PLC now owns 11,610 shares of the company’s stock valued at $346,000 after purchasing an additional 1,306 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in shares of Sanuwave Health during the 2nd quarter worth $46,000. Institutional investors and hedge funds own 42.53% of the company’s stock.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.